VRDN

Viridian TherapeuticsB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$61.00

+273.1% vs current

Most likely

Base case

60%

Probability

Target price

$41.71

+155.1% vs current

B-

Bear case

20%

Probability

Target price

$26.00

+59.0% vs current

AI sentiment snapshot

Latest data as of 2026-01-15

AI commentary

Consensus is mildly constructive—analyst averages cluster in the mid‑40s, implying upside from the anchor [#SERP-2][#SERP-3]. Near‑term sentiment is event‑driven and cautious given binary clinical readouts and cash‑runway risk; expect headline volatility around disclosures [#SERP-5]. Coverage dispersion (high 61.00, low ≈26.00) highlights divergent outcomes and elevated event sensitivity [#SERP-8].

RankAlpha Sentiment AI - 2026-01-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-15catalystQuarterly update / cash runway disclosureHigh impact

Quarterly financial update and commentary on cash runway that can materially change dilution and near‑term valuation expectations [#SERP-2].

2026-06-30eventLate‑stage clinical readout (assumed window end)High impact

Potential phase 2/3 or pivotal readout assumed to complete by window end; date is conservative assumption for market reaction and is used because no single public deadline is listed [#SERP-3].

2027-01-15catalystCommercial progress / reimbursement milestonesHigh impact

Longer‑term commercialization and payor/reimbursement progress could drive sustained upside if favorable; timing conservatively set one year out due to typical regulatory and market access timelines [#SERP-8].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-15 • Updated nightlySource: Internal modelMethodology